VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY
Publication
, Conference
Desjardins, A; Vredenburgh, JJ; Gururangan, S; Peters, KB; Friedman, AH; Friedman, H; Reardon, DA
Published in: NEURO-ONCOLOGY
2009
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
2009
Volume
11
Issue
5
Start / End Page
634 / 634
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Vredenburgh, J. J., Gururangan, S., Peters, K. B., Friedman, A. H., Friedman, H., & Reardon, D. A. (2009). VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY. In NEURO-ONCOLOGY (Vol. 11, pp. 634–634).
Desjardins, Annick, James J. Vredenburgh, Sridharan Gururangan, Katherine B. Peters, Allan H. Friedman, Henry Friedman, and David A. Reardon. “VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY.” In NEURO-ONCOLOGY, 11:634–634, 2009.
Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Friedman AH, Friedman H, et al. VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY. In: NEURO-ONCOLOGY. 2009. p. 634–634.
Desjardins, Annick, et al. “VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY.” NEURO-ONCOLOGY, vol. 11, no. 5, 2009, pp. 634–634.
Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Friedman AH, Friedman H, Reardon DA. VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY. NEURO-ONCOLOGY. 2009. p. 634–634.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
2009
Volume
11
Issue
5
Start / End Page
634 / 634
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences